Table 2:
The clinical and pathological characteristics of NR patients.
| NR patients | ||||||
|---|---|---|---|---|---|---|
| Characteristics/number | 1 | 2 | 3 | 4 | 5 | 6 |
| Age at diagnosis, years | 73 | 35 | 51 | 44 | 56 | 23 |
| Gender | M | M | M | M | F | M |
| Course of disease, years | 2 | 2 | 4 | 2 | 2 | 7 |
| BMI at diagnosis, kg/m2 | 23.9 | 30.86 | 24.4 | 25 | 25.3 | 31.8 |
| BP at diagnosis, mmHg | 120/80 | 135/78 | 126/76 | 130/86 | 108/64 | 115/74 |
| eGFR at diagnosis, mL/min/1.73 m2 (CKD-EPI) | 69 | 89.1 | 75.6 | 102.8 | 74.4 | 132.9 |
| Creatinine at diagnosis, µmol/L | 94 | 95 | 99 | 80 | 77 | 62 |
| 24 h UTP at diagnosis, g/day | 5.74 | 12.8 | 10.3 | 4.98 | 4.77 | 13.53 |
| Albumin at diagnosis, g/L | 27.4 | 20.6 | 27.3 | 16 | 24 | 25 |
| Serum PLA2R at diagnosis, RU/mL | 521.09 | 17.61 | ND | 91.24 | <2 | <2 |
| Complication | Hypetension/diabetes/stroke | Gout | No | No | No | No |
| Immunosuppressor | Tacrolimus/CTX | Rituximab/tacrolimus | CTX/cyclosporin | Tacrolimus | Rituximab/tacrolimus | Rituximab/tacrolimus/CTX |
| MN class | II | III | I | I | I | II |
| IF IgG | 3+ | 3+ | 3+ | 3+ | 3+ | 3+ |
| IF IgA | Neg | Neg | Neg | Neg | Neg | Neg |
| IF C3 | 2+ | 3+ | 2+ | 1+ | 1+ | 1+ |
| IF C1q | Neg | Neg | Neg | Neg | Neg | Neg |
| Tissue PLA2R | Pos | Pos | Pos | Pos | Pos | Pos |
| Global sclerosis (%) | 17 | 5 | 6 | 3 | 17 | 0 |
| Segmental sclerosis | 0/29 | 0/20 | 0/18 | 0/31 | 0/30 | 0/7 |
| Crescent | 0/29 | 0/20 | 0/18 | 0/31 | 0/30 | 0/7 |
| Interstitial fibrosis (%) | 10 | 40 | 5 | 5 | 10 | 40 |
| Mesangial matrix increase | Neg | Mild | Neg | Mild | Neg | Neg |
| Interstitial lymphocytes | Mild | Mod | Neg | Neg | Mild | Neg |
| Arterial sclerosis | Mild | Mild | Mild | Mild | Mild | Neg |
M: male; F: female; BMI: body mass index BP: blood pressure; UTP: urine total protein; CTX: cyclophosphamide; Neg: negative; Pos: positive.